Jun 02, 2021 / 12:00PM GMT
Julia Neugebauer - MorphoSys AG - Director of Corporate Communications & IR
Welcome, ladies and gentlemen. My name is Julia Neugebauer, Senior Director of Investor Relations. It's my pleasure to welcome you to our (technical difficulty) Constellation Pharmaceuticals and our strategic funding partnership with Royalty Pharma, which we announced earlier this morning.
You'll find a brief presentation in the Media and Investors section on our website, morphosys.com, under the section MorphoSys Events or by visiting our transaction web page at morphosys-constellation-royaltypharma.com.
Before we begin, I'd like to remind you on Slide 2 that some of the statements we make during the call are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans as well as the development plans of our collaboration partners. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys 20-F and annual
MorphoSys AG To Acquire Constellation Pharmaceuticals M&A Call Transcript
Jun 02, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers